PROM1 and acute lymphoblastic leukemia: Proof-of-principle studies have shown that targeting CD133 can be used to deliver nanoparticles to gastric stem cells [3], or for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemias (ALL) caused by rearrangements of the Mixed Lineage Leukemia (MLL) gene [4].